FDA grants fast track designation to cellular immunotherapy for metastatic breast cancer

The FDA granted fast track designation to Bria-IMT, an investigational cell-based therapy for the treatment of women with metastatic breast cancer.
Bria-IMT (SV-BR-1-GM, BriaCell Therapeutics) is a gene-edited, granulocyte-macrophage colony-stimulating factor-secreting breast cancer cell line derived from grade II biopsied tumor samples. The cells express HLA class I and class II antigens.
The cells are irradiated and given as an inoculation at four separate sites. Bria-IMT is provided as part of a regimen that includes low-dose cyclophosphamide before and interferon-alpha-2-beta after

The FDA granted fast track designation to Bria-IMT, an investigational cell-based therapy for the treatment of women with metastatic breast cancer.
Bria-IMT (SV-BR-1-GM, BriaCell Therapeutics) is a gene-edited, granulocyte-macrophage colony-stimulating factor-secreting breast cancer cell line derived from grade II biopsied tumor samples. The cells express HLA class I and class II antigens.
The cells are irradiated and given as an inoculation at four separate sites. Bria-IMT is provided as part of a regimen that includes low-dose cyclophosphamide before and interferon-alpha-2-beta after